Fresenius Medical Care today announced that the company has extended the end-date under the merger agreement with NxStage Medical, Inc. to account for the interruption of the Federal Trade Commission’s review of the transaction during the recent U.S. government shutdown.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, is still in the process of seeking approval by the U.S. Federal Trade Commission (FTC) for its acquisition of NxStage Medical, Inc. (“NxStage”) and therefore now expects the transaction to close in early 2019.
Unicyte AG, a subsidiary of Fresenius Medical Care, has initiated a long-term research collaboration with Prof. Dr. Tobias B. Huber of Germany’s Medical Center Hamburg-Eppendorf (UKE) to explore the molecular and cellular mechanisms of kidney diseases.
The Supervisory Board of Fresenius Medical Care AG & Co. KGaA has decided to propose PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft as the auditor for the financial year 2020.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, has decided to update the market early by providing its indicative preliminary assumptions for the business development in 2019.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, continues to expand its dialysis care network through the acquisition of further dialysis centers and renal hospitals in China.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today released the following statement in response to the defeat of the ballot initiative Proposition 8 in California.
Patient growth continues across all regions Operating margin in North America improved to 18.5% in the third quarter Dialysis Care revenue growth in North America of 6% (+5% at constant currency)
Anticipated revenue decrease of around 6% on a reported basis and an increase of around 2% on a comparable basis (+3% at constant currency)